GeneDx Holdings (WGS) Net Cash Flow (2020 - 2026)

GeneDx Holdings (WGS) has reported Net Cash Flow for 7 consecutive years, with -$33.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Cash Flow fell 31.36% year-over-year to -$33.6 million in Q2 2026; TTM through Jun 2026 was -$13.8 million, a 176.47% decrease from a year earlier, with the FY2025 full-year figure at $19.8 million, up 236.78% from the prior year.
• Net Cash Flow was -$33.6 million for Q2 2026 at GeneDx Holdings, down from -$11.1 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $76.6 million in Q1 2023 and troughed at -$93.3 million in Q3 2022.
• A 5-year average of -$18.9 million and a median of -$16.4 million in 2022 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow slumped 239.85% in 2023 and soared 1101.76% in 2025, its largest moves.
• Over 5 years, Net Cash Flow stood at -$67.4 million in 2022, then jumped by 118.36% to $12.4 million in 2023, then soared by 120.67% to $27.3 million in 2024, then plunged by 66.94% to $9.0 million in 2025, then sank by 472.12% to -$33.6 million in 2026.
• The last three Net Cash Flow figures came in at -$33.6 million (Q2 2026), -$11.1 million (Q1 2026), and $9.0 million (Q4 2025), per Business Quant data.